Michael Bernhardt, MD
Dermatology · Jacksonville, FLNPI 1386695054
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $614,748 of the $749,860 with a category attached, or 82.0%. 43 manufacturers reported payments, led by Lilly USA, LLC at 26.9% of the total. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,255 payments — averaging $597.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$202K
- E.r. Squibb & Sons, L.L.C.$164K
- Sanofi$97K
- Regeneron Healthcare Solutions, Inc.$78K
- UCB, Inc.$59K
- Pfizer$41K
- plus $109K from 37 others
Across 46 payments — averaging $4247.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$147K
- Incyte Corporation$31K
- Almirall LLC$6K
- Next Science LLC$6K
- Eli Lilly$6K
What the payments were for
- Consulting fees$56,1907%
- Speaking & faculty fees$614,74882%
- Travel & lodging$50,7877%
- Food & beverage$27,6754%
- Education$4600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$749,860 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyjuvekBeremagene Geperpavec-Svdt | 30 | $728,805 |
| Dupixent PenDupilumab | 109 | $460,263 |
| Skyrizi PenRisankizumab-Rzaa | 19 | $404,375 |
| Dupixent SyringeDupilumab | 82 | $336,088 |
| Cosentyx Unoready PenSecukinumab | 25 | $238,837 |
| Humira(Cf) PenAdalimumab | 11 | $194,778 |
| TremfyaGuselkumab | 11 | $144,635 |
| Taltz AutoinjectorIxekizumab | 17 | $128,667 |
| OtezlaApremilast | 20 | $77,529 |
| OpzeluraRuxolitinib Phosphate | 34 | $68,980 |
| AdbryTralokinumab-Ldrm | 11 | $41,323 |
| ZoryveRoflumilast | 25 | $21,531 |
| Tacrolimus | 86 | $8,586 |
| WinleviClascoterone | 11 | $6,176 |
| Ketoconazole | 262 | $5,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Krystal Biotech IncVyjuvek | $115 | $728,80530 claims |
| Johnson & JohnsonTremfya | $3,613 | $144,63511 claims |
| AmgenOtezla | $534 | $77,52920 claims |
| Incyte CorporationOpzelura | $40,622 | $68,98034 claims |
| LEO Pharma Inc.Adbry | $716 | $41,32311 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $11,546 | $21,53125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Jacksonville
- Josep Genebriera-De LamoJacksonville$140K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.